文献速递头颈外科咽喉与嗓音

喉基底样鳞状细胞癌:美国国家癌症数据库分析

Basaloid Squamous Cell Carcinoma of the Larynx: A National Cancer Database Analysis.
PubMed 文献 · Otolaryngol Head Neck Surg · 2019-02-05

该回顾性分析查询美国国家癌症数据库(NCDB)2004至2014年治疗的440例喉基底样鳞状细胞癌(BSCC)患者,中位随访31.2个月。单因素分析中手术、手术加放疗、手术加放化疗、放疗、放化疗各治疗方式生存获益无差异;多因素分析仅放化疗与5年总生存改善相关(HR 0.587,95%CI 0.37-0.93,P=0.022)。

要点

  • 多因素分析中放化疗与喉BSCC的5年总生存改善相关(HR 0.587,95%CI 0.37-0.93,P=0.022)。
  • 单因素分析中手术、手术加放疗、手术加放化疗、放疗、放化疗的生存获益无差异。
  • 各治疗方式在I-II期(P=0.340)和III-IV期(P=0.154)肿瘤间表现相似。

核心结论

  • 本研究是迄今最大宗的喉BSCC系列。
  • 多因素分析发现放化疗与喉BSCC的5年总生存改善相关。

研究设计与样本

  • 回顾性分析。
  • 数据来自美国国家癌症数据库(NCDB),查询2004至2014年治疗的喉基底样鳞状细胞癌(BSCC)患者。
  • 共纳入440例符合入选标准的患者,中位随访31.2个月。
  • 采用Kaplan-Meier法确定5年总生存率,用单因素和多因素分析识别与5年总生存相关的因素。

主要发现

  • 单因素分析中,所评估的治疗方式(单纯手术、手术加放疗、手术加放化疗、放疗、放化疗)生存获益无差异。
  • 多因素分析中,仅放化疗与生存改善相关(风险比0.587;95%CI 0.37-0.93;P=0.022)。
  • 各治疗方式在I期和II期肿瘤间表现相似(P=0.340),在III期和IV期肿瘤间也表现相似(P=0.154)。

关键数值与推荐

  • 多因素分析中放化疗的风险比为0.587(95%CI 0.37-0.93,P=0.022)。
  • 各治疗方式在I-II期肿瘤间比较的P=0.340,在III-IV期肿瘤间比较的P=0.154。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Basaloid squamous cell histology is a rare variant that accounts for about 2% of all head and neck squamous cell laryngeal carcinomas. The purpose of this study was to examine overall survival rates of patients according to treatment, stage, and laryngeal subsite. STUDY DESIGN: Retrospective analysis. SETTING: National Cancer Database (NCDB). SUBJECTS AND METHODS: The NCDB was queried for patients with basaloid squamous cell carcinoma (BSCC) who were treated from 2004 to 2014. Five-year overall survival rates were determined by the Kaplan-Meier method. Univariate and multivariate analysis was used to identify factors correlated with 5-year overall survival. RESULTS: The NCDB identified 440 patients meeting inclusion criteria. Median follow-up time was 31.2 months. On univariate analysis, the treatment modalities assessed (surgery alone, surgery with radiotherapy, surgery with chemoradiotherapy, radiotherapy, chemoradiotherapy) did not differ in their survival benefit. On multivariate analysis, only chemoradiotherapy (hazard ratio, 0.587; 95% CI, 0.37-0.93; P = .022) was associated with improved survival. All treatment modalities performed similarly between stage I and II tumors ( P = .340) and stage III and IV tumors ( P = .154). CONCLUSION: This study represents the largest laryngeal BSCC series to date. We found that chemoradiotherapy was associated with improved 5-year overall survival of laryngeal BSCC on multivariate analysis.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Jumaily M, Faraji F, Zhang D, et al. Basaloid Squamous Cell Carcinoma of the Larynx: A National Cancer Database Analysis. Otolaryngol Head Neck Surg. 2019. PMID: 30717636. doi:10.1177/0194599818816299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。